BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 16192600)

  • 21. Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy.
    Pichler H; Möricke A; Mann G; Teigler-Schlegel A; Niggli F; Nebral K; König M; Inthal A; Krehan D; Dworzak MN; Janousek D; Harbott J; Schrappe M; Gadner H; Strehl S; Haas OA; Panzer-Grümayer R; Attarbaschi A;
    Br J Haematol; 2010 Apr; 149(1):93-100. PubMed ID: 20067563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
    Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma.
    Burkhardt B; Woessmann W; Zimmermann M; Kontny U; Vormoor J; Doerffel W; Mann G; Henze G; Niggli F; Ludwig WD; Janssen D; Riehm H; Schrappe M; Reiter A
    J Clin Oncol; 2006 Jan; 24(3):491-9. PubMed ID: 16421426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia.
    Conter V; Aricò M; Basso G; Biondi A; Barisone E; Messina C; Parasole R; De Rossi G; Locatelli F; Pession A; Santoro N; Micalizzi C; Citterio M; Rizzari C; Silvestri D; Rondelli R; Lo Nigro L; Ziino O; Testi AM; Masera G; Valsecchi MG;
    Leukemia; 2010 Feb; 24(2):255-64. PubMed ID: 20016536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881.
    Hutchinson RJ; Gaynon PS; Sather H; Bertolone SJ; Cooper HA; Tannous R; Wells LM; Heerema NA; Sailer S; Trigg ME;
    J Clin Oncol; 2003 May; 21(9):1790-7. PubMed ID: 12721256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of standard-risk acute lymphoblastic leukemia in children: the results of protocol AL841 from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
    Matsuzaki A; Okamura J; Ishii E; Ikuno Y; Koga H; Eguchi H; Yanai F; Inada H; Nibu K; Hara T; Take H; Miyazaki S; Tasaka H
    Pediatr Hematol Oncol; 1999; 16(3):187-99. PubMed ID: 10326217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study.
    Heath JA; Steinherz PG; Altman A; Sather H; Jhanwar S; Halpern S; Pieters R; Shah N; Steinherz L; Tannous R; Terry W; Trigg ME;
    J Clin Oncol; 2003 Apr; 21(8):1612-7. PubMed ID: 12697887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study.
    Klug Albertsen B; Schmiegelow K; Schrøder H; Carlsen NT; Rosthøj S; Avramis VI; Jakobsen P
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):117-20. PubMed ID: 12172975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95.
    Schrauder A; Reiter A; Gadner H; Niethammer D; Klingebiel T; Kremens B; Peters C; Ebell W; Zimmermann M; Niggli F; Ludwig WD; Riehm H; Welte K; Schrappe M
    J Clin Oncol; 2006 Dec; 24(36):5742-9. PubMed ID: 17179108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol.
    Bajel A; George B; Mathews V; Viswabandya A; Kavitha ML; Srivastava A; Chandy M
    Pediatr Blood Cancer; 2008 Nov; 51(5):621-5. PubMed ID: 18688848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Preliminary study on the safety and pharmacodynamic action of low dose L-asparaginase].
    Wu ZL; Chen FX; Ye TZ; Lai YH; Cui YQ; Zou YW; Lu CY; Lan SL; Zhong GY; Guan JM; Wei FG; Zhang H
    Zhonghua Xue Ye Xue Za Zhi; 2006 Jan; 27(1):14-6. PubMed ID: 16732932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Malignant non-Hodgkin's lymphoma of childhood and adolescence in Austria--therapy results between 1986 and 2000.
    Attarbaschi A; Mann G; Dworzak M; Trebo M; Urban C; Fink FM; Horcher E; Reiter A; Riehm H; Gadner H;
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):978-86. PubMed ID: 12635465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].
    Skoczeń S; Balwierz W; Moryl-Bujakowska A; Pawińska K; Luszczyńska A; Balcerska A; Płoszyńska A; Chybicka A; Dobaczewski G; Juszczak K; Wachowiak J; Derwich K; Kowalczyk J; Wiśniewska-Slusarz H; Matysiak M; Krauze A; Pawelec K; Sońta-Jakimczyk D; Tomaszewska R; Wysocki M; Styczyńskii J; Swiatkiewicz V;
    Przegl Lek; 2006; 63(1):11-4. PubMed ID: 16892892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Research on the pharmacokinetics and pharmacodynamics of L-asparaginase during its treatment of childhood acute lymphoblastic leukemia].
    Chen FX; Cui YQ; Wu ZL; Ye TZ; Lai YH; Zou YW; Lu CY; Guan JM; Wei FG; Zhang H
    Zhonghua Xue Ye Xue Za Zhi; 2005 Feb; 26(2):100-2. PubMed ID: 15921627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004.
    Kamps WA; van der Pal-de Bruin KM; Veerman AJ; Fiocco M; Bierings M; Pieters R
    Leukemia; 2010 Feb; 24(2):309-19. PubMed ID: 20016528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment results in children with the standard risk acute lymphoblastic leukemia treated with high dose of methotrexate (5.0 g/m2). 11 years of the Polish Pediatric Leukemia/Lymphoma Study Group experience].
    Derwich K; Wachowiaki J; Kaczmarek-Kanoldi M; Balcerska A; Balwierz W; Chybicka A; Kowalczyk JR; Matysiak M; Jackowska T; Sońta-Jakimczyk D; Wysocki M; Chełmecka-Hanuszewicz L; Cwiklińska M; Kołtan A; Malinowska I; Odój T; Płoszyńska A; Steczowicz M; Wojciechowska V; Wójtowicz A;
    Przegl Lek; 2006; 63(1):7-10. PubMed ID: 16892891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation between high vascular endothelial growth factor-A serum levels and treatment outcome in patients with standard-risk acute lymphoblastic leukemia: a report from Children's Oncology Group Study CCG-1962.
    Avramis IA; Panosyan EH; Dorey F; Holcenberg JS; Avramis VI;
    Clin Cancer Res; 2006 Dec; 12(23):6978-84. PubMed ID: 17145817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.
    Ribera JM; Oriol A; Sanz MA; Tormo M; Fernández-Abellán P; del Potro E; Abella E; Bueno J; Parody R; Bastida P; Grande C; Heras I; Bethencourt C; Feliu E; Ortega JJ
    J Clin Oncol; 2008 Apr; 26(11):1843-9. PubMed ID: 18398150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
    Einsiedel HG; von Stackelberg A; Hartmann R; Fengler R; Schrappe M; Janka-Schaub G; Mann G; Hählen K; Göbel U; Klingebiel T; Ludwig WD; Henze G
    J Clin Oncol; 2005 Nov; 23(31):7942-50. PubMed ID: 16258094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of a randomized trial of hyperfractionated cranial radiation therapy for treatment of high-risk acute lymphoblastic leukemia: therapeutic efficacy and neurotoxicity.
    Waber DP; Silverman LB; Catania L; Mautz W; Rue M; Gelber RD; Levy DE; Goldwasser MA; Adams H; Dufresne A; Metzger V; Romero I; Tarbell NJ; Dalton VK; Sallan SE
    J Clin Oncol; 2004 Jul; 22(13):2701-7. PubMed ID: 15226337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.